Galapagos NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Galapagos confirms completion of BioFocus and Argenta divestiture
Galapagos NV:Confirms completion of transaction announced on March 13 to sell BioFocus and Argenta service division operations to Charles River Laboratories International for up to 134 million euros.All closing conditions of definitive agreement have been met.Purchase price 129 million euros in cash, subject to certain post-closing working capital adjustments.Galapagos eligible to receive 5 million euros earnout payment after 12 months, upon achievement of revenue target for divested service division.
Latest Developments for Galapagos NV
- Galapagos updates on products clinical trials
- Galapagos says GSK2586184 met primary endpoint in Phase 2a psoriasis study
- Galapagos NV to present favorable pre-clinical data on GLPG1790, selective ephrin receptor kinase inhibitor, at AACR in San Diego
- Charles River Laboratories International Inc to acquire the CRO Services Division of Galapagos NV
- Share this
- Digg this